Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2017 Summary Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 3, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Ophthalmology, Gastrointestinal, Hematological Disorders, Central Nervous System, Respiratory, Cardiovascular and Genito Urinary System And Sex Hormones which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL), Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergies, Alzheimer's Disease, Anaphylactic Shock, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Leukemias, Lupus Erythematosus, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Skin Inflammation, Solid Tumor and Systemic Lupus Erythematosus. Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development AB Science SA Almirall SA Archer Pharmaceuticals Inc Asana BioSciences LLC Beijing Hanmi Pharmaceutical Co Ltd Celgene Corp Clevexel Pharma SAS F. Hoffmann-La Roche Ltd Fujifilm Corp Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Hutchison China MediTech Ltd Japan Tobacco Inc Levolta Pharmaceuticals Inc Merck KGaA Millennium Pharmaceuticals Inc Portola Pharmaceuticals Inc Rigel Pharmaceuticals Inc Taiho Pharmaceutical Co Ltd TopiVert Ltd Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles AB-8779 - Drug Profile Product Description Mechanism Of Action R&D Progress ASN-002 - Drug Profile Product Description Mechanism Of Action R&D Progress C-13 - Drug Profile Product Description Mechanism Of Action R&D Progress CC-509 - Drug Profile Product Description Mechanism Of Action R&D Progress cerdulatinib - Drug Profile Product Description Mechanism Of Action R&D Progress CVXL-0074 - Drug Profile Product Description Mechanism Of Action R&D Progress entospletinib - Drug Profile Product Description Mechanism Of Action R&D Progress FF-10102 - Drug Profile Product Description Mechanism Of Action R&D Progress fostamatinib disodium - Drug Profile Product Description Mechanism Of Action R&D Progress GS-9876 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2646264 - Drug Profile Product Description Mechanism Of Action R&D Progress HMPL-523 - Drug Profile Product Description Mechanism Of Action R&D Progress JTE-852 - Drug Profile Product Description Mechanism Of Action R&D Progress LAS-189386 - Drug Profile Product Description Mechanism Of Action R&D Progress nilvadipine - Drug Profile Product Description Mechanism Of Action R&D Progress PRT-2761 - Drug Profile Product Description Mechanism Of Action R&D Progress RO-9021 - Drug Profile Product Description Mechanism Of Action R&D Progress SKIO-703 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit SYK for Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress TAK-659 - Drug Profile Product Description Mechanism Of Action R&D Progress TAS-5567 - Drug Profile Product Description Mechanism Of Action R&D Progress TOP-1210 - Drug Profile Product Description Mechanism Of Action R&D Progress TOP-1288 - Drug Profile Product Description Mechanism Of Action R&D Progress TOP-1630 - Drug Profile Product Description Mechanism Of Action R&D Progress TOP-1890 - Drug Profile Product Description Mechanism Of Action R&D Progress Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones Featured News & Press Releases May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017 Mar 16, 2017: Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis Jan 30, 2017: Fostamatinib Study Results Continue to Trend Positive Jan 10, 2017: Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China Dec 06, 2016: Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome Nov 14, 2016: Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting Nov 03, 2016: Takeda to Present Clinical Data on TAK-659 During 58th American Society of Hematology Annual Meeting Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AB Science SA, H1 2017 Pipeline by Almirall SA, H1 2017 Pipeline by Archer Pharmaceuticals Inc, H1 2017 Pipeline by Asana BioSciences LLC, H1 2017 Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017 Pipeline by Celgene Corp, H1 2017 Pipeline by Clevexel Pharma SAS, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Fujifilm Corp, H1 2017 Pipeline by Genosco Inc, H1 2017 Pipeline by Gilead Sciences Inc, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Hutchison China MediTech Ltd, H1 2017 Pipeline by Japan Tobacco Inc, H1 2017 Pipeline by Levolta Pharmaceuticals Inc, H1 2017 Pipeline by Merck KGaA, H1 2017 Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Pipeline by Portola Pharmaceuticals Inc, H1 2017 Pipeline by Rigel Pharmaceuticals Inc, H1 2017 Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 Pipeline by TopiVert Ltd, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
